Amarin Corporation plc announces that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk and elevated triglycerides (= 150 mg/ml [= 1.7 mmol/l) and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor. The national reimbursement will now allow Amarin to begin commercialization efforts of VAZKEPA across Portugal as of August 1, 2024. According to Statistics Portugal (Instituto Nacional de Estatística - INE), the prevalence of established cardiovascular disease in the adult population between 45 and 79 years of age in Portugal is 10.7%.

The growing prevalence of cardiovascular risk factors in the country has resulted in more than 35,000 annual deaths from cardiovascular disease, constituting 29% of the total mortality in 2017. These figures demonstrate a clear need for action to reduce the immense burden of this disease on patients, their families, and the Portuguese healthcare system. Amarin continues to advance its pricing and reimbursement discussions in a number of other European markets to drive patient access across the region and will share updates as these become available.